FDA
-
-
-
-
-
-
-
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
-
-
-
-
-
-
Nexalin Technology and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
-
-
-
-
-
-
New to The Street to Air Show #683 on Bloomberg, Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals
-
-
-
-
-
-
-
BioVie Announces Data Highlighting Bezisterim’s Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference
-
-
-
-
-
-
-
BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025)
-
-
-
-
-
-
-
SECURITIES FRAUD CLASS ACTIONS SURVIVE MOTIONS TO DISMISS: Grabar Law Office Investigates Claims on Behalf of Shareholders of Arqit Quantum Inc. (NASDAQ: ARQQ); Axsome Therapeutics, Inc. (NASDAQ: AXSM
-
327,796 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

